HRTX - Heron Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Heron Therapeutics, Inc.

4242 Campus Point Court
Suite 200
San Diego, CA 92121
United States
858-251-4400
http://www.herontx.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees198

Key Executives

NameTitlePayExercisedYear Born
Dr. Barry D. QuartPres, CEO & Director1.18M6.05M1957
Mr. Robert E. Hoffman CPA, CPACFO & Sr. VP of Fin.579.93k686.23k1966
Mr. John W. PoyhonenExec. VP, Chief Commercial Officer & Director62.5kN/A1960
Ms. Kimberly J. ManhardExec. VP of Drug Devel. & Director825.14k624.56k1960
Mr. David L. SzekeresSr. VP of Bus. Devel., Gen. Counsel & Corp. Sec.N/AN/A1974
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy; and HTX-011, an investigational, long-acting, and extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for post-operative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Corporate Governance

Heron Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 5. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.